Clinical Trial Update: Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria [Phase 2]

View source ↗

Summary

Phase 2 trial update on liposomal amikacin for inhalation (LAI) for nontuberculous mycobacterial infections; study completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nontuberculous Mycobacterial Infections

Drugs mentioned

• Liposomal Amikacin for Inhalation (amikacin liposome inhalation suspension)

Snippet

Sponsor: Insmed Incorporated | Conditions: Mycobacterium Infections, Nontuberculous | Phase 2 | Status: COMPLETED | Results posted: 2019-08-21